Waleed Ghanima

Waleed Ghanima is a Professor II in the Department of Haematology at the University of Oslo's Faculty of Medicine. His research focuses on immune thrombocytopenia (ITP), thrombosis, pulmonary embolism, and their clinical management. He collaborates extensively with international teams, contributing to studies on treatment algorithms, biomarkers, and patient outcomes. Key affiliations include the TROLL registry and clinical trials evaluating anticoagulants like apixaban and novel therapies such as rilzabrutinib.

He has been involved in investigations of SARS-CoV-2-related thrombosis and post-COVID-19 complications, emphasizing the interplay between systemic inflammation and blood disorders. His work bridges basic science and clinical practice, with a strong emphasis on improving quality-of-life metrics for patients with chronic blood conditions. Recent studies address residual perfusion defects post-pulmonary embolism and the role of exercise rehabilitation in mitigating persistent symptoms.

His contributions span translational research, including drug efficacy evaluations (e.g., fostamatinib, avatrombopag) and diagnostic tool optimization (e.g., clinical scores for DVT). He also explores the impact of comorbidities and treatment interactions, particularly in cancer-associated thrombosis.